Effects of phosphodiesterase (PDE) inhibitors on human ether‐a‐go‐go related gene (hERG) channel activity

It is presumed that phosphodiesterase (PDE) inhibitors have two mechanisms for inhibition of hERG currents in the acute applications to cells: direct channel block, and downregulation of human ether‐a‐go‐go related gene (hERG) activities by PKA‐dependent pathway mediated phosphorylation through their inhibitory effects against PDE enzymes. However, it is unknown whether PDE inhibition contributes to the inhibitory effects of PDE inhibitors on hERG currents. This study examined the effects of various PDE inhibitors on hERG currents using both the whole‐cell and perforated patch‐clamp techniques in hERG transfected CHO‐K1 cells. The study also investigated the contribution of the PKA‐dependent pathway to the inhibitory effects of PDE inhibitors on hERG currents. Of the PDE inhibitors tested, vinpocetine, erythro‐9‐(2‐hydroxy‐3‐nonyl) adenine (EHNA), vesnarinone, rolipram and dipyridamole decreased hERG currents in a concentration‐dependent manner. Vinpocetine and vesnarinone markedly decreased the hERG current with an IC 50of 0.13 and 20.6 µm, respectively, at comparatively low concentrations. Furthermore, vinpocetine caused a cumulative block of hERG currents. Milrinone, amrinone and zaprinast had no effect on the hERG current up to 100 µm. Of the PDE3 inhibitors (vesnarinone, amrinone and milrinone), only vesnarinone showed an hERG inhibitory effect. The inhibitory effects of vinpocetine and vesnarinone were not significantly affected by the co‐application of protein kinase inhibitors. Furthermore, the protein kinase activators had no effect on hERG currents. It is concluded that vinpocetine and vesnarinone block the hERG channel directly, and that the inhibitory effect on intracellular PDE in the PKA‐dependent pathway may not be involved in the inhibition of hERG currents in hERG transfected CHO‐K1 cells. Copyright © 2006 John Wiley & Sons, Ltd.

[1]  S. Sasayama,et al.  Sustained inotropic effects of a new cardiotonic agent. OPC‐8212 in patients with chronic heart failure , 1989, Clinical cardiology.

[2]  T. Yanagisawa,et al.  Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart. , 1984, Arzneimittel-Forschung.

[3]  R. Owens,et al.  Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors. , 1999, Biochemical pharmacology.

[4]  C. Obejero-Paz,et al.  Mechanisms of arsenic-induced prolongation of cardiac repolarization. , 2004, Molecular pharmacology.

[5]  E. Marbán,et al.  Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. , 1996, Circulation research.

[6]  I Kodama,et al.  Open channel block of HERG K(+) channels by vesnarinone. , 2001, Molecular pharmacology.

[7]  A. Schwartz,et al.  Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212 , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  R. Pederson,et al.  Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway* , 2002, The Journal of Biological Chemistry.

[9]  P. Palade,et al.  Perforated Patch Recording with β-escin , 1998, Pflügers Archiv.

[10]  J. Kimura,et al.  Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor. , 2003, Biological & pharmaceutical bulletin.

[11]  R. Horn,et al.  Muscarinic activation of ionic currents measured by a new whole-cell recording method , 1988, The Journal of general physiology.

[12]  L. Fu,et al.  Perforated patch recording of L-type calcium current with beta-escin in guinea pig ventricular myocytes. , 2003, Acta pharmacologica Sinica.

[13]  Jules C Hancox,et al.  High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. , 2004, Biochemical and biophysical research communications.

[14]  Y. Kurachi,et al.  Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. , 2000, The Journal of pharmacology and experimental therapeutics.

[15]  I Kodama,et al.  Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current. , 1997, Circulation.

[16]  Y. Kuryshev,et al.  Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.

[17]  N. Standen,et al.  Activation of ATP‐dependent K+ channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. , 1995, The Journal of physiology.

[18]  T. Mori,et al.  In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals. , 1984, Arzneimittel-Forschung.

[19]  N. Taira,et al.  Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. , 1987, The Journal of pharmacology and experimental therapeutics.

[20]  C. Nichols,et al.  Protein kinase C inhibition of cloned inward rectifier (HRK1/KIR2.3) K+ channels expressed in Xenopus oocytes. , 1996, The Journal of physiology.

[21]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[22]  J. Daly,et al.  Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Charles M Beasley,et al.  Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil. , 2004, European journal of pharmacology.

[24]  W. Kübler,et al.  HERG Potassium Channel Activation Is Shifted by Phorbol Esters via Protein Kinase A-dependent Pathways* , 1998, The Journal of Biological Chemistry.

[25]  R. North,et al.  An amino acid mutation in a potassium channel that prevents inhibition by protein kinase C. , 1992, Science.

[26]  M. Houslay,et al.  Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. , 1995, The Biochemical journal.

[27]  Y. Kuryshev,et al.  HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. , 2005, Journal of pharmacological and toxicological methods.

[28]  W. Kübler,et al.  Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A* , 1999, The Journal of Biological Chemistry.

[29]  R. Kass,et al.  Regulation of a heart potassium channel by protein kinase A and C. , 1988, Science.

[30]  I. Pastan,et al.  Characterization of cyclic AMP-resistant Chinese hamster ovary cell mutants lacking type I protein kinase. , 1981, The Journal of biological chemistry.